This newsletter, the sixth since the ETERNAL project started, provides ample opportunities to dig deeper into both the project’s research illuminating the environmental risks surrounding pharmaceutical manufacture and positive responses from the industry to minimize the risks through technological innovation and standardization for less impactful, more efficient, sustainable and safe by design processes.

A newly published, peer-reviewed paper from a cross-partner team of authors from the ETERNAL project assess the EU's strategy and proposed legislation for pharmaceuticals against the latest scientific knowledge about potential risks to biota and human health, identifying opportunities for strengthening the protection that it offers.

The first annual meeting of the group of EU funded projects on Green Pharmaceuticals was held on 10th December 2024 in Brussels. Hosted by the European Commission, representatives of the ETERNAL project and our four sister projects currently within the cluster provided updates on the projects' objectives and progress, and had productive discussions with a range of stakeholders from across the Community.

A newly released public deliverable of the ETERNAL project lays out the key-drivers and a possible regulatory roadmap for “compliant-by-design” strategies applying the concepts of “greener design” to be delivered in Europe.